Ciclosporin: prescribe by brand

Ciclosporin should be prescribed and dispensed by brand, according to new advice issued by the MHRA.

As a critical-dose drug, ciclosporin has a narrow therapeutic window; consequently, even minor differences in bioavailability can affect blood levels, side effects and transplant function.

The MHRA's recommendations state that brands of ciclosporin (these include Neoral, Sandimmun and Deximune) should not be considered interchangeable unless careful therapeutic monitoring takes place.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases